Landmarks in this family-owned company, now headed by the founder’s grandson, Matthieu Frechin.

In brief

2013 :	80 years of the Group
2012 :	- A foothold in the field of Behavior with the acquisition of laboratory Orsco and its flagship Zylkène®. -
2011 :	- Acquisition of Farmagricola S.A. Importaçao e Exportaçao in Brazil - Launch of Forcyl® (Infectious Diseases, livestock animals) and Cimalgex® (Pain & Inflammation, Pets)
2010 :	- Registration of Marbocyl® 2% and 10% in Japan. - Start of the Acacia project, the new extension for development and production of innovative tablets at the parent company site. - Launch of Kefloril® and Ceftiocyl®, two new antibiotics for livestock animals.
2009 :	- Creation of the Asia-Pacific Division - Acquisition of Wockhardt animal health and creation of Vétoquinol India - Launching of Request, a group of European experts in anti-infectives - Launching of the 3D communication campaign, that values the three therapeutic fields of the Group
2008 :	- Acquisition of Ascor Chimici in Italy - Creation of a development unit in Canada - Acquisition of Viavet in Scandinavia - Launch of Vetprofen® (anti-inflammatory) - Launch of Rubénal (nephrology)
2007 :	- Vétoquinol Unipessoal Lda created, 17th subsidiary of the group in Portugal. - Launch of Alfaxan® (anesthetic)
2006 :	- Vétoquinol’s presence on Asian market expanded with the acquisition of its South Korean distributor, Semyung Vet. - Stock exchange listing, in the Eurolist market of Euronext Paris (Compartment B, mnemonics: VETO ; ISIN code FR0004186856). - Acquisition of Vet Solutions, American independent veterinary company located in Fort Worth, Texas (United States)
2005 :	Launch of Clavaseptin®, a palatable antibiotic for dogs and cats.
2004 :	- Sales office opened in Shanghai, China. Biological research discontinued. Vétoquinol concentrates on developing curative products. - Debut of company’s new strapline: "Sign of Passion"
2003 :	- International launch of Propalin®, treatment for urinary incontinence in ovariectomised bitches. Marbocyl® is supplied in palatable tablets form. - New research and development centre opens.
2002 :	- Vétoquinol moves into the international market for the first time with the acquisition of Evsco and Tomlyn ranges in the USA. - Launch of Prilium®, the 1st liquid ACE inhibitor for heart failure in dogs demonstrates new service levels to veterinarians including innovative drug development, first international scientific symposium and prescription training.
2001 :	- Vétoquinol acquires Swiss group Chassot and expands its nutraceuticals range. - Launches Aurizon®, a treatment for otitis in dogs.
1999 :	Following acquisition of Webster in Canada, Vétoquinol is confirmed as a market leader.
1998 :	Takeover of MECA in Germany.
1995 :	In Europe, Vétoquinol launches Marbocyl®, a high quality antibiotic researched by Vétoquinol. Within three years, it becomes a major product in the market.
1994 :	Acquisition of Immunovet in the USA.
1992 :	Vétoquinol Mexico founded. Vétoquinol North America buys Austin and Dispar in Canada.
1991 :	Vétoquinol acquires Antibioticos Pharma Vet in Spain, renamed Vétoquinol Especialidades Veterinarias.
1990 :	Vétoquinol acquires Univet in the UK and founds Vétoquinol North America, Canada. They in turn acquire Multivet and MVE.
1987 :	Vétoquinol launches Tolfedine®, an anti-inflammatory set to become the French market leader and acquires Psyphac in Belgium.
1984 :	Galvet Ltd founded in Ireland.
1980 :	R&D centre opened to provide technical support for Vétoquinol.
1977 :	Vetam, the first overseas subsidiary, founded in the Netherlands.
1975 :	New French laws introduced for veterinary products. Vétoquinol adapts to these becoming increasingly professionally aware.
1962 :	Becomes "Vétoquinol S.A" , exclusively devoted to animal health. Facilities transfer from Lure, Haute Saône to Magny-Vernois. Étienne Frechin, son of Joseph Frechin and our current President, joins the company.
1956 :	Production of medicines for human use is discontinued.
1933 :	- Joseph Frechin founds the Laboratoires Biochimiques de l’Est, for human products, in Lure, Haute-Saone. - He develops the first quinoline-based veterinary product: Vétoquinol.